Search PubMed⌕ Search

Biomedical subjects

Nathan B Fountain

Publications and source records attributed to Nathan B Fountain.

4 recordsLinked to original sources

Epilepsy.

Seizures are common and are treated in all branches of medicine. Approximately 10% of the population will have one or more seizures during their lifetime. Seizures are symptoms that occur in acute illness, ie, provoked seizures, or in epilepsy, ie, unprovoked seizures. Epilepsy is any disorder in which spontaneous recurrence of unprovoked seizures is the main symptom. It is a common chronic neurologic disorder and affects 1% to 3% of the population. Classification of seizure type is important because it enables identification of the region of the brain where the seizure originated and guides initial diagnostic testing. Classification of epilepsy syndrome, rather than only type of seizure, is more important. Epilepsy syndromes are defined by many factors, including type of seizures, age at onset of seizures, family history of seizures, and findings at physical examination, electroencephalography (EEG), and neurologic imaging studies. Identifying the epilepsy syndrome provides insight into natural history, prognosis, diagnostic testing, and therapy of the disorder and facilitates communication between health care professionals. Understanding seizure type provides useful information even when the epilepsy syndrome cannot be classified. Many sudden events are easily confused with seizures, in particular, pseudoseizures, syncope, migraine, cerebrovascular disease, movement disorders, and sleep disorders. In most cases a detailed history and physical examination concentrated on the details of the event, and results of routine EEG and magnetic resonance imaging can aid in determination of which events are seizures. Video EEG monitoring is occasionally necessary to capture events to enable definitive determination of whether they are seizures and to further characterize them. Provoked seizures are treated with relief of the provoking factor. Antiepileptic drugs (AEDs) are not indicated. However, AEDs may be required to treat unprovoked seizures of new onset in patients at high risk for seizure recurrence or when a second seizure can have devastating psychosocial effects. High risk for recurrence is present when there is a history of brain insult, an EEG demonstrates epileptiform abnormalities, and magnetic resonance images demonstrate a structural lesion. AED therapy is the standard treatment for epilepsy, ie, two or more seizures. Selection of the appropriate AED depends on type of seizure and epilepsy present, and individual drug characteristics, including pharmacokinetics, side effects, dosing interval, and cost. All available AEDs except ethosuximide are effective as adjunctive therapy, and most are effective as initial monotherapy for partial seizures. Generalized seizures preferentially respond to valproate, lamotrigine, and topiramate, among other drugs. If trials of more than two AEDs do not control seizures, additional AEDs are unlikely to be effective, and the patient should be referred to an epilepsy center, where other treatment options, in particular, epilepsy surgery, can be offered. Epilepsy surgery renders 60% to 70% of patients with temporal lobe epilepsy free of disabling seizures.

Adult↗

Epilepsy and athletics.

It may seem logical to place restrictions on athletes with epilepsy, but there are no studies to suggest that even contact sports exacerbate seizures, and there is ample evidence that exercise reduces seizure frequency and improves well-being. Thus, sports participation should generally be encouraged for epilepsy patients. The risk-benefit analysis for an individual patient is highly dependent on the athletic activity considered; type of seizure, the likelihood that a seizure will occur during the activity, and comorbid conditions. Water sports (scuba diving, swimming, boating), sports performed at heights (piloting, sky diving, climbing, horseback riding), and motor sports require specific considerations.

Athletic Injuries↗

Clinical correlation of occipital intermittent rhythmic delta activity.

Frontal intermittent rhythmic delta activity is associated with encephalopathy, and temporal intermittent delta activity is associated with epilepsy, but the importance of OIRDA (OIRDA) is less well defined. The authors reviewed retrospectively EEGs and medical records of 77 patients with OIRDA to determine whether they had epilepsy, acute encephalopathy, or another diagnosis. They compared the incidence of epilepsy in this population with a control group of 77 patients referred for EEG, matched for age, gender, and year of EEG. OIRDA was most commonly generalized, high amplitude, saw toothed, and reactive to eye opening, and with mean frequency of 2.89 +/- 0.50 Hz. Mean age was 8.1 +/- 4.5 years. Seventy-six of 77 patients were <or= 18 years old. Seizures were present in 69 OIRDA patients but only 41 control subjects (P < 0.0001). OIRDA compared with control subjects had more patients with GTCs (34 vs. 10; P < 0.0001) and absence seizures (25 vs. 6; P < 0.0001), but an equal number had partial seizures (30 vs. 27). Only one OIRDA patient had acute encephalopathy. OIRDA patients with seizures were younger (7.6 +/- 4.7 years vs. 12 +/- 6.9 years; P < 0.01) and more likely to evolve to spike-wave activity compared with OIRDA patients without seizures. OIRDA is present almost exclusively in children and is associated with epilepsy but not acute encephalopathy. OIRDA has clinical importance distinctly different from frontal intermittent rhythmic delta activity.

Age Factors↗

Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial.

PURPOSE: To assess the efficacy and safety of levetiracetam (LEV) as adjunctive therapy in children with treatment-resistant partial-onset seizures. METHODS: Children (aged 6-12 years) with treatment-resistant partial-onset seizures receiving one standard antiepileptic drug (AED) were eligible. After a 4-week baseline period, children received LEV in a 6-week titration phase (target dose, 40 mg/kg/day) followed by an 8-week evaluation phase. Seizure frequency during the evaluation period with individualized LEV doses (20-40 mg/kg/day) were compared with the 4-week baseline seizure frequency. Plasma concentrations of LEV and other AEDs were determined to evaluate potential drug interactions. RESULTS: Twenty-four subjects enrolled and received LEV; 23 entered the evaluation phase, and 22 completed the evaluation phase. Compared with their baseline seizure frequency, 12 (52%) of 23 subjects entering the evaluation phase had their seizure frequency decrease by >50%. Two subjects remained seizure free during the entire evaluation period. LEV did not significantly affect plasma concentrations of any concomitant AED during this study, and no alteration of mean clinical laboratory values was observed. The most commonly reported adverse events were headache, infection, anorexia, and somnolence. CONCLUSIONS: This open-label study of adjunctive LEV therapy (at 20-40 mg/kg/day) suggests that LEV is effective, safe, and well tolerated in children ages 6-12 years with treatment-resistant partial-onset seizures. A randomized, placebo-controlled, double-blind trial of LEV adjunctive therapy in children with treatment-resistant partial-onset seizures is needed and ongoing to confirm these open-label findings.

Age Factors↗